The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PALI | +28.65% | -99.95% | -77.72% | -100% |
| S&P | +14.77% | +87.2% | +13.35% | +66% |
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.
No news articles found for Palisade Bio.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$1.00K | 0.0% |
| Market Cap | $7.84M | 86.4% |
| Market Cap / Employee | $979.96K | 0.0% |
| Employees | 8 | -11.1% |
| Net Income | -$2,868.00K | 17.8% |
| EBITDA | -$2,921.00K | 18.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.23M | -35.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $211.00K | -40.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -137.67% | -31.1% |
| Return On Invested Capital | -125.40% | -6.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3,553.00K | -13.4% |
| Operating Free Cash Flow | -$3,553.00K | -13.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.30 | 0.11 | 0.56 | 1.58 | 357.03% |
| Price to Sales | 21.88 | - | |||
| Price to Tangible Book Value | 0.30 | 0.11 | 0.56 | 1.58 | 357.03% |
| Enterprise Value to EBITDA | 2.27 | 1.69 | 0.64 | -0.48 | -173.71% |
| Return on Equity | -153.6% | -170.7% | -188.5% | -228.6% | 68.16% |
| Total Debt | $169.00K | $58.00K | $338.00K | $211.00K | -40.90% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
